Back to top
more

Mirum Pharmaceuticals (MIRM)

(Delayed Data from NSDQ)

$24.02 USD

24.02
317,121

-0.40 (-1.64%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $24.03 +0.01 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for MIRM

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Mirum Pharmaceuticals, Inc. [MIRM]

Reports for Purchase

Showing records 1 - 20 ( 96 total )

Company: Mirum Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

04/23/2024

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Mirum Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

03/18/2024

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Mirum Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

03/14/2024

Company Report

Pages: 9

FDA Approves LIVMARLI for PFIC; Model Updates Lead to Raising Our PT to $58

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Mirum Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

02/29/2024

Company Report

Pages: 7

4Q Recap: 2024 Global Net Product Sales Guidance Set to $310-$320M, But OpEx Higher Too; Reduce PT to $45

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Mirum Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

02/27/2024

Company Report

Pages: 6

4Q Preview and Model Updates for a 2024 Top Pick; Multiple Near-Term Catalysts Abound; Affirm Buy, $58 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Mirum Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

02/13/2024

Company Report

Pages: 9

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Mirum Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

01/31/2024

Daily Note

Pages: 114

2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Company: Mirum Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

01/30/2024

Daily Note

Pages: 115

2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Company: Mirum Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

01/22/2024

Company Report

Pages: 9

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Mirum Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

01/09/2024

Company Report

Pages: 5

Preliminary 2023 LIVMARLI Net Sales And Topline Figures Exceed Our Estimates; Expecting an Eventful 2024; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Mirum Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

01/08/2024

Industry Report

Pages: 5

New Drug Prices for the New Year; We Highlight Three Recent Price Changes in Our Coverage Universe

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Mirum Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

12/18/2023

Company Report

Pages: 5

LIVMARLI Was Safe in EMBARK For Biliary Atresia But Missed Primary and Key Secondary Endpoints; Moderating PT to $58

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Mirum Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

12/05/2023

Daily Note

Pages: 4

LIVMARLI Approved For ALGS in Italy; We Expect LIVMARLI''s PFIC FDA Approval by March 13, 2024 PDUFA Date; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Mirum Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

11/22/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for MIRM 112223

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Mirum Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

11/03/2023

Company Report

Pages: 10

3Q Recap: LIVMARLI Drives Significant Topline Beat; EMBARK Topline Data On Target By YE2024; PT Down to $60

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Mirum Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

10/18/2023

Daily Note

Pages: 3

FDA Extended LIVMARLI sNDA Review For PFIC By Three Months; PDUFA Pushed Back to March 13, 2024; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Mirum Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

09/13/2023

Daily Note

Pages: 4

Mirum Appoints New CFO With Rare Disease Experience

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Mirum Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

08/04/2023

Company Report

Pages: 9

2Q Recap; LIVMARLI Approaching December 13 PFIC PDUFA Date; Bile Acid Products Acquisition to Close in 3Q; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Mirum Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

07/18/2023

Company Report

Pages: 10

Mirum Adds Two Bile Acid Products For Rare Diseases;Transaction to Close in 3Q23; Increasing PT to $63; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Mirum Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

06/15/2023

Daily Note

Pages: 5

Hepatology Publication Provides Key Evidence of Improved Prognosis in ALGS Patients Treated With LIVMARLI; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party